Social media posts discuss known AstraZeneca vaccine risk of blood clots

In court documents from an ongoing lawsuit in the U.K., vaccine manufacturer AstraZeneca acknowledged that the blood clotting condition thrombosis with thrombocytopenia syndrome (TTS) is a rare risk associated with its COVID-19 vaccine. This story has been misleadingly framed as a “bombshell admission” on social media despite TTS being a known rare risk of both the AstraZeneca and Johnson & Johnson COVID-19 vaccines since 2021. AstraZeneca recently withdrew the vaccine from the global market due to a decline in demand, a decision that some vaccine opponents falsely claim is because of the TTS risk.

Recommendation: Medium Risk Read More +

About Us

The Public Health Communications Collaborative (PHCC) was developed in response to the urgent need for timely, relevant, and practical tools, messaging, and training to support and enhance the communications capacity of public health professionals across the country. Learn More >>

Sign Up for Public Health Alerts

About Us

The Public Health Communications Collaborative (PHCC) was formed in 2020 to coordinate and amplify public health messaging on COVID-19 and increase Americans’ confidence in guidance from the Centers for Disease Control and Prevention (CDC) and state and local public health officials.

Learn More

Recent Misinformation Alerts